Zivo Bioscience Inc (OTCMKTS:ZIVO) Director Christopher D. Maggiore purchased 490,125 shares of the stock in a transaction on Friday, January 3rd. The shares were purchased at an average price of $0.16 per share, with a total value of $78,420.00.
Shares of OTCMKTS:ZIVO opened at $0.16 on Wednesday. Zivo Bioscience Inc has a 52 week low of $0.04 and a 52 week high of $0.18. The company’s 50 day moving average is $0.13 and its two-hundred day moving average is $0.10.
Zivo Bioscience (OTCMKTS:ZIVO) last announced its quarterly earnings data on Monday, October 28th. The biotechnology company reported ($0.01) earnings per share for the quarter.
About Zivo Bioscience
Zivo Bioscience, Inc, together with its subsidiaries, develops natural bioactive ingredients derived from its proprietary algal cultures. The company focuses on licensing and selling its natural bioactive ingredients to animal, human and dietary supplement, and medical food manufacturers; and license its bioactive molecules as lead compounds or templates for synthetic variants intended for therapeutic applications.
Recommended Story: What is the definition of a trade war?
Receive News & Ratings for Zivo Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zivo Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.